ChiCTR2100053045 版本V1.3 版本创建时间2022/09/05 21:26:51 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2100053045 

最近更新日期:

Date of Last Refreshed on:

2022-09-05 21:22:56 

注册时间:

Date of Registration:

2021-11-10 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

数字替身下对精神分裂症幻听的心理治疗

Public title:

Psychotherapy of auditory hallucinations in schizophrenia under digital Avarta

注册题目简写:

English Acronym:

研究课题的正式科学名称:

数字替身下对精神分裂症幻听的心理治疗

Scientific title:

Psychotherapy of auditory hallucinations in schizophrenia under digital Avarta

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

张骏 

研究负责人:

张骏 

Applicant:

Zhang Jun 

Study leader:

Zhang Jun 

申请注册联系人电话:

Applicant telephone:

+86 18980602251

研究负责人电话:

Study leader's telephone:

+86 18980602251

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

1025159956@qq.com

研究负责人电子邮件:

Study leader's E-mail:

1025159956@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

四川成都市武侯区国学巷37号

研究负责人通讯地址:

四川成都市武侯区国学巷37号

Applicant address:

37 Guoxue Lane, Wuhou District, Chengdu, Sichuan

Study leader's address:

37 Guoxue Lane, Wuhou District, Chengdu, Sichuan

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

四川大学华西医院

Applicant's institution:

West China Hospital of Sichuan University

研究负责人所在单位:

四川大学华西医院

Affiliation of the Leader:

West China Hospital of Sichuan University

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2020(328)

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

四川大学华西医院生物医学伦理审查委员会

Name of the ethic committee:

Ethics Committee of West China Hospital of Sichuan University

伦理委员会批准日期:

Date of approved by ethic committee:

2020-06-20 00:00:00

伦理委员会联系人:

邓邵林

Contact Name of the ethic committee:

Deng Shaolin

伦理委员会联系地址:

四川成都市武侯区国学巷37号

Contact Address of the ethic committee:

37 Guoxue lane, Wuhou District, Chengdu

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

四川大学华西医院

Primary sponsor:

West China Hospital of Sichuan University

研究实施负责(组长)单位地址:

四川成都市武侯区国学巷37号

Primary sponsor's address:

37 Guoxue Lane, Wuhou District, Chengdu, Sichuan, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

四川

市(区县):

成都

Country:

China

Province:

Sichuan

City:

Chengdu

单位(医院):

四川大学华西医院

具体地址:

武侯区国学巷37号

Institution
hospital:

West China Hospital of Sichuan University

Address:

37 Guoxue Lane, Wuhou District

经费或物资来源:

四川大学华西医院学科卓越发展1·3·5工程临床研究孵化项目

Source(s) of funding:

1·3·5 project for disciplines of excellence–Clinical Research Incubation Project, West China Hospital, Sichuan University

Target disease:

Schizophrenia

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

探索出一套适合中国人的数字替身软件辅助下的幻听心理治疗操作技术。  

Objectives of Study:

To explore a set of auditory hallucination psychotherapy technology assisted by digital avatar software suitable for Chinese people.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1.所有参与者均签署书面知情同意;
2.诊断为精神分裂症谱系障碍(ICD-10 f20-29),有持续的听幻觉;
3.年龄16岁-45岁,会说会读中文;
4.所有参与者在试验前都服用过抗精神病药物,但他们的听幻觉对先前的治疗没有反应或只是部分反应;
5.所有受试者需同意继续接受标准的抗精神病药物治疗。

Inclusion criteria

1. All participants signed written informed consent;
2. Diagnosed with schizophrenia spectrum disorder (ICD-10 f20-29) with persistent auditory hallucinations;
3. Aged 16-45 years, can speak and read Chinese;
4. All participants had taken antipsychotic drugs before the trial, but their auditory hallucinations did not respond or only partially responded to previous treatment;
5. All subjects must agree to continue to receive standard antipsychotic medication.

排除标准:

1.精神症状严重不能完成有效访谈和自评量表者;
2.正在接受精神病的其他心理治疗;
3.被诊断患有器质性脑疾病;
4.因物质滥用导致的幻听。

Exclusion criteria:

1. Those with severe mental symptoms who cannot complete effective interviews and self-assessment scales;
2. Are receiving other psychotherapy for mental illness;
3. Diagnosed with organic brain disease;
4. Auditory hallucinations caused by substance abuse.

研究实施时间:

Study execute time:

From 2020-06-01 00:00:00 To 2023-05-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2021-12-01 00:00:00 To 2023-03-01 00:00:00  

干预措施:

Interventions:

组别:

干预组

样本量:

10

Group:

intervention group

Sample size:

干预措施:

数字替身心理治疗

干预措施代码:

Intervention:

psychotherapy with digital Avatar

Intervention code:

组别:

对照组

样本量:

10

Group:

control group

Sample size:

干预措施:

心理支持

干预措施代码:

Intervention:

psychological support

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

四川 

市(区县):

成都 

Country:

China 

Province:

Sichuan 

City:

Chengdu 

单位(医院):

四川大学华西医院 

单位级别:

三级甲等 

Institution
hospital:

West China Hospital of Sichuan University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

PSYRAT幻听量表得分

指标类型:

主要指标

Outcome:

PSYRAT Auditory Hallucinations Scale Score

Type:

Primary indicator

测量时间点:

基线和12周

测量方法:

精神症状评定量表(PSYRAT)

Measure time point of outcome:

baseline and 12 weeks

Measure method:

Psychiatric Symptom Rating Scale (PSYRAT)

指标中文名:

幻听信念(BAVQ-R)得分

指标类型:

主要指标

Outcome:

Auditory hallucinations belief (BAVQ-R) score

Type:

Primary indicator

测量时间点:

基线和12周

测量方法:

幻听信念问卷(BAVQ-R)

Measure time point of outcome:

baseline and 12 weeks

Measure method:

Auditory Beliefs Questionnaire (BAVQ-R)

指标中文名:

PANSS评分表

指标类型:

主要指标

Outcome:

Scores of PANSS

Type:

Primary indicator

测量时间点:

基线和12周

测量方法:

阳性及阴性症状量表(PANSS)

Measure time point of outcome:

baseline and 12 weeks

Measure method:

Positive and Negative Syndrome Scale (PANSS)

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

N/A

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 16 years
最大 Max age 45 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

随机数字表

Randomization Procedure (please state who generates the random number sequence and by what method):

Random number table

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

2024-1-1 请说明共享原始数据的方式

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Jan.1st, 2024

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form, CRF

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2021-11-10 13:46:33